Fact.MR – A Market Research and Competitive Intelligence Provider: The global benign prostatic hyperplasia treatment market size is forecast to total US$ 12 Bn by 2027, opines Fact.MR.
Nearly Half of Benign Prostatic Hyperplasia (BPH) Treatment Sales to be Accounted by BPH Drugs
In a recent market analysis, Fact.MR covers the current scenario of the global benign prostatic hyperplasia treatment market, including drivers, trends, opportunities, and restraints. The report divulges compelling insights into segments of the market such as treatment type and end users across seven regions.
Fact.MR – A Market Research and Competitive Intelligence Provider: The global benign prostatic hyperplasia (BPH) treatment market size is forecast to total US$ 12 Bn by 2027, opines Fact.MR. Increasing incidence of benign prostatic hyperplasia (BPH) among geriatric population has underpinned the need for superior treatment options, which is creating a conducive environment for the growth in the market.
BPH is a disease that affects males during the aging process. Rising geriatric population, especially males, is driving the incidence of BPH, resulting in higher demand for therapeutics. This is projected to propel the demand for effective treatment solutions, augmenting the growth in the BPH market.
Further, various drugs used for BPH treatment such as Avodart, Cialis, and Jalyn are approaching their patent expiration dates, which is paving way for generic drugs. This is expected to create lucrative opportunities for players for offering effective and accessible treatment options.
For More Information On How To Improve Your Benign Prostatic Hyperplasia Treatment Market Footprint, Request A Sample Here
https://www.factmr.com/connectus/sample?flag=S&rep_id=4412
In addition to this, adoption of BPH drugs is expected to remain high in the forthcoming years. Availability of short and long-term alpha inhibitors which improves blood flow is a chief factor driving sales in the BPH treatment market.
However, introduction of surgeries and therapeutics, coupled with rising awareness regarding the side effects of these drugs is boosting the demand for minimally-invasive surgeries. As per Fact.MR, this segment is projected to surpass the valuation of the drug class segment over the assessment period.
“Demand for BPH treatment in Asia Pacific is projected to grow on the back of growing trend of medical tourism. Besides this, introduction of generic and low-cost drug variants will continue augmenting the growth of the market over the forecast period," says a Fact.MR analyst.
Key Takeaways:
- Based on treatment type, the drug class segment is projected to hold nearly 50% of the total market share.
- In terms of end users, hospitals will account for a dominant share of the market over the forecast period.
- Demand for benign prostatic hyperplasia treatment will continue rising in the U.S. due to the presence of robust healthcare industry.
- Sales will grow considerably in India, favoured by increasing medical tourism in the country for BPH treatment.
- China is expected to be placed as a lucrative market due to favourable government policies supporting the expansion of the healthcare sector.
Growth Drivers:
- BPH awareness programs will encourage patients to seek effective diagnosis and treatment, which in turn will fuel sales.
- Collaborations among market players and research institutes to develop new BHP drug and treatment options will augment growth in the market.
To gain in-depth insights on Benign Prostatic Hyperplasia Treatment Market, request methodology at
https://www.factmr.com/connectus/sample?flag=RM&rep_id=4412
Competitive Landscape
Leading players are focusing on research and development to launch cost-effective and easily available drugs for Benign Prostatic Hyperplasia treatment. Besides this, players are investing in mergers, acquisitions, and collaborations to strengthen their distribution networks and expand their production capacities.
For instance, in May 2020, Asahi Kasei Pharma, one of the key players in the BPH market gained the approval for Flivas (naftopidil) in China, an agent for treatment of dysuria associated with BPH.
Key Players in the Benign Prostatic Hyperplasia Treatment Market Include:
- Abbott
- Allergan Plc
- Astellas Pharma, Inc.
- Asahi Kasei Corporation
- Boehringer Ingelheim GmbH
- GlaxoSmithKline Plc.
- Pfizer, Inc.
- Sanofi SA
- Teva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- Boston Scientific Corporation
- Teleflex Incorporated
- Endo International Plc.
- Urologix, LLC
- LISA Laser
- Olympus
- Others
More Valuable Insights on Benign Prostatic Hyperplasia Treatment Market
Fact.MR provides an unbiased analysis of the benign prostatic hyperplasia treatment market, presenting historical demand data (2017-2019) and forecast statistics for the period from 2020-2027. The study divulges compelling insights on the global benign prostatic hyperplasia treatment market with a detailed segmentation on the basis of:
Treatment Type:
- Drug Classes
- Alpha Blockers
- 5-Alpha-reductase Inhibitors (5-ARIs)
- Phosphodiesterase-5 Enzyme Inhibitors
- Others
- Minimally-invasive Surgeries
- Transurethral Resection of the Prostate (TURP)
- Transurethral Incision of the Prostate (TUIP)
- Robotic Surgeries
- Transurethral Microwave Thermotherapy (TUMT)
- Prostatic Urethral Lift
- Others
- Laser Therapy
- Others
End User:
- Hospitals
- Ambulatory Surgical Centres
- Specialty Clinics
- Others
Regions:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- MEA
Key Questions Covered in Benign Prostatic Hyperplasia Treatment Market Report
- The report offers insight into the benign prostatic hyperplasia treatment market demand outlook for 2020-2027.
- The market study also highlights projected sales growth for benign prostatic hyperplasia treatment market between 2020 and 2027.
- Benign prostatic hyperplasia treatment market survey identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry.
- Benign prostatic hyperplasia treatment market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, joint ventures, collaborations or partnerships, and others.
Explore Fact.MR’s Coverage on the Healthcare Domain -
Prostate Cancer Diagnostics Market Analysis - The prostate cancer diagnostics market is predicted to profit from an expanding geriatric population in the developed countries, as well as access to high-quality healthcare. Both the government and commercial providers are increasing their healthcare spending by leaps and bounds. In order to assess the impact of treatment diagnosis on prostate cancer patients, key companies in the global prostate cancer diagnostics market are partnering with regional health ministries and medical administrators.
Nonmetastatic Castrationresistant Prostate Cancer NMCRPC Therapeutics Market Scope - The growth of the Non-metastatic Castration-Resistant Prostate Cancer (nmCRPC) Therapeutics market is predicted to be slowed by a decrease in diagnostic and treatment adoption, which will result in fewer visits to healthcare facilities. There has been a substantial shift in focus among pharmaceutical and biopharmaceutical companies to create coronavirus diagnostic kits and treatment options, resulting in a consistent growth rate of the Non-metastatic Castration-Resistant Prostate Cancer (nmCRPC) Therapeutics market.
Minimally Invasive Surgery Market Forecast - The global minimally invasive surgery is growing. Supplier sales are predicted to be fueled by advancements in clinics, hospitals, and medical technology, as well as an increase in preference for less invasive surgical techniques such as robotic surgery, laparoscopic surgery, and others. The demand for bariatric and cosmetic minimally invasive surgery is also increasing in different parts of the world. The United States, Germany, France, India, Japan, and a few other nations, according to the report, will continue to be attractive markets for minimally invasive surgeries and MIS techniques.
About Fact.MR
Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to chemical and materials, technology to even the most niche categories. 80% of Fortune 1000's trust us in critical decision making.
MarketNgage is powered by Fact.MR – our Unified Intelligence Engine, a revolutionary Market Research Subscription platform with a flexible pricing to suit your needs.
You can access all our chemical and materials research reports by signing up with MarketNgage’s Market Research Subscription with FREE credits. MarketNgage is powered by Fact.MR – A Fully integrated research solution for seamless single-window access Widest coverage on emerging markets, nascent products, and disruptive technologies.
Contact:
Mahendra Singh
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Source: Fact.MR